(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 26 August 2004 (26.08.2004)

PCT

(10) International Publication Number WO 2004/072262 A3

- (51) International Patent Classification7: C12N 5/00, 5/02, 5/06, 5/08, 5/10, A61K 39/00, 38/39
- (21) International Application Number:

PCT/US2004/003974

- (22) International Filing Date: 10 February 2004 (10.02.2004)
- (25) Filing Language:

60/446,474

English

(26) Publication Language:

English

(30) Priority Data:

10 February 2003 (10.02.2003) US

- (71) Applicant (for all designated States except US): NORTHWEST BIOTHERAPEUTICS, INC. [US/US]; 22322-20th Avenue S.E., Suite 150, Bothell, WA 98021 (US).
 - (72) Inventors; and
 - (75) Inventors/Applicants (for US only): SHANKAR, Gopi [IN/US]; 400 Char Sam Boulevard, Chester Springs, PA 19425 (US). LODGE, Patricia A., [US/US]; 10332 21st Avenue West, Everett, WA 98024 (US). PESTANO, Linda, A. [US/US]; 11630 N. Dragoon Springs Drive, Oro Valley, AZ 85737 (US).
 - (74) Agents: POOR, Brian W., et al.; TOWNSEND and TOWNSEND and CREW, LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).
 - (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 24 March 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CULTURED CD14+ ANTIGEN PRESENTING CELLS

(57) Abstract: The present invention provides isolated CD14+ antigen presenting cells, e.g., dendritic cells and isolated and enriched populations thereof as well as methods for isolation and enrichment. Also provided are methods for using the CD14+ antigenpresenting cells to modulate T cell responses in vivo, in vitro, and ex vivo.

INTERNATIONAL SEARCH REPORT		Γ	International application No	
			PCT/US04/03974	
A. CLASSIFICATION OF SUBJECT MATTER IPC(7): C12N 5/00, 5/02, 5/06, 5/08, 5/10; A61K 39/00, 38/39 US CL: 435/325, 355, 372; 424/184.1, 277.1 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) U.S.: 435/325, 355, 372; 424/184.1, 277.1				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) WEST, Medline, Caplus, Promt, Biosis, Embase				
	MENTS CONSIDERED TO BE RELEVANT		····	
Category *				Relevant to claim No.
X Y	SHORTMAN, K., et al. Mouse and Human Dendritic Cell Subsets. Nat. Rev. Immunol. March 2002, Vol. 2, pages 151-161, see entire document.			1-4 5-49
X ENGERING, A., et al. Subset of DC-SIGN+ dendritic cells in human blood transmits HIV-1			5	
	to T lymphocytes. Blood. 1 September 2002, Vol. 100			
Y	Y document.			1-4 and 6-49
Y	HORIGUCHI, Y., et al. Screening of HLA-A24-restri specific Membrane Antigen That Induce Specific Anti-Cancer Res. December 2002, Vol. 8, pages 3885-3892	itumor Cytotoxic T L		1-49
				<u> </u>
Further	documents are listed in the continuation of Box C.	See paten	t family annex.	•
 Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance 		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E" carlier application or patent published on or after the international filing date		"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means		when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report		
28 November 2004 (28.11.2004)			JAN 2005	
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents		Authorized officer G. R. Ewoldt, Ph.I	ganulat.	Shabaraje

G. R. Ewoldt, Ph.D.

Telephone No. 571-272-1600

P.O. Box 1450 Alexandria, Virginia 22313-1450

Commissioner for Patents

Facsimile No. (703) 305-3230